| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL-26; AK155 |
| Entrez GeneID | 55801 |
| WB Predicted band size | Calculated MW: 20 kDa; Observed MW: 20 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human IL-26 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇与IL-26抗体相关的研究文献示例(信息基于公开研究总结，非真实文献，仅供参考)：
---
1. **文献名称**: *"IL-26 promotes neutrophil-mediated inflammation via antibody-dependent mechanisms in psoriasis"*
**作者**: Meller S, et al.
**摘要**: 研究揭示了IL-26通过结合自身抗体(如抗-DNA抗体)形成免疫复合物，激活中性粒细胞并加剧银屑病皮肤炎症，提示抗IL-26抗体可能成为治疗靶点。
2. **文献名称**: *"Therapeutic targeting of IL-26 in rheumatoid arthritis: A monoclonal antibody approach"*
**作者**: Che K, et al.
**摘要**: 开发了一种抗IL-26单克隆抗体，在类风湿性关节炎小鼠模型中显著抑制关节炎症和骨质破坏，表明靶向IL-26的抗体治疗具有临床潜力。
3. **文献名称**: *"IL-26 as a biomarker for inflammatory bowel disease: Detection by antibody-based assays"*
**作者**: Damoiseaux C, et al.
**摘要**: 建立了一种高灵敏度的ELISA检测方法(基于抗IL-26抗体)，证实炎症性肠病患者血清和肠道组织中IL-26水平升高，支持其作为疾病活动度的生物标志物。
---
(注：以上文献为示例性内容，实际研究中请通过PubMed等数据库查询真实文献。)
Interleukin-26 (IL-26), a member of the IL-10 cytokine family, is primarily produced by activated T cells (particularly Th17 subsets) and natural killer (NK) cells. It plays dual roles in immune regulation, exhibiting both pro-inflammatory and antimicrobial properties. Structurally, IL-26 binds to a heterodimeric receptor complex (IL-10R2/IL-20R1) and activates JAK-STAT signaling pathways, influencing epithelial and immune cell responses. Its unique ability to form complexes with self-DNA amplifies TLR9-mediated inflammatory responses, linking it to autoimmune diseases like rheumatoid arthritis and psoriasis.
IL-26 antibodies, including monoclonal and polyclonal variants, are critical research tools for detecting IL-26 expression in tissues or biological fluids. They enable mechanistic studies of IL-26's involvement in chronic inflammation, mucosal immunity, and host defense against intracellular pathogens. Therapeutic IL-26-neutralizing antibodies are under preclinical investigation for autoimmune conditions, leveraging their potential to block IL-26-mediated inflammatory cascades. Conversely, agonist antibodies are explored for enhancing antimicrobial responses in infections. Challenges remain in balancing therapeutic efficacy with safety, given IL-26's complex roles across different disease contexts. Current research also focuses on IL-26 as a biomarker for disease activity in inflammatory bowel disease and chronic lung disorders.
×
